Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Montserrat Zanui"'
Autor:
Margarita Romeo, Marta Gil-Martín, Lydia Gaba, Iris Teruel, Álvaro Taus, Claudia Fina, Maria Masvidal, Paola Murata, Julen Fernández-Plana, Alejandro Martínez, Cristina Pérez, Yolanda García, Valerie Rodriguez, Sara Cros, Marta Parera, Montserrat Zanui, Silvia Catot, Beatriz Pardo, Andrea Plaja, Anna Esteve, Maria Pilar Barretina-Ginesta
Publikováno v:
Cancers
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
Cancers; Volume 14; Issue 18; Pages: 4414
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
Cancers; Volume 14; Issue 18; Pages: 4414
Simple Summary Since the irruption of PARPi in the therapeutic armamentarium for ovarian cancer, concerns regarding post-progression treatment outcomes have emerged, owing to known crossed-resistance mechanisms between PARPi and platinum. In this mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea56cb82745ed2816479a78c7958bbe4
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7061
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7061
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
Autor:
Miriam Cuatrecasas, Pilar Escudero, Hermini Manzano, José Ramón Muñoz Rodríguez, Montserrat Zanui, Mireia Gil, Carlos Fernández-Martos, Xabier García-Albéniz, Julen Fernández-Plana, Carmen Alonso, Vicente Alonso, Miguel Cadena Méndez, Federico Rojo, Uriel Bohn, Ester Falcó, Joan Maurel, Antonia Salud, Jaime Feliu, Javier Gallego, V. Calderero
Publikováno v:
The Oncologist
This articles compares the capacity of several biomarkers (BRAF mutation, PIK3CA mutation/PTEN loss and DP phenotype) to predict 12‐month progression‐free survival and compares it with that of clinical variables
Background. RAS testing is us
Background. RAS testing is us
Autor:
Marta Martin-Richard, Carlos Fernández-Martos, Veronica Fernández, Xabier García-Albéniz, José Ramón Muñoz Rodríguez, Antonieta Salud, Bart Claes, Mireia Gil-Raga, E. Falcó, Jaime Feliu, Federico Rojo, Òscar Reig, Vicente Alonso, Joan Maurel, Beatriz Bellosillo, Marta Mendiola, Jorge Aparicio, Miguel M. Méndez, Hermini Manzano, Pilar Escudero, Bart Jacobs, Ferran Torres, Clara Montagut, Javier Gallego, Erwin Sablon, Geert Maertens, Montserrat Zanui, Julen Fernández-Plana, Jose Carlos Mendez
Publikováno v:
Jco Precision Oncology
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
JCO Precision Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
JCO Precision Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
PURPOSE RAS and BRAF mutations can be detected as a mechanism of acquired resistance in circulating tumor (ct) DNA in patients with metastatic colorectal cancer treated with anti–epidermal growth factor receptor therapy. METHODS RAS and BRAF mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f28688c1976de7aba93e577105de3e6
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=11513
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=11513
Publikováno v:
Cancer Treatment Reviews. 39:584-591
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy of the pleura associated with exposure to asbestos. Its incidence is anticipated to increase over the next 10years in both Europe and the developing nations. In advanced disease
Autor:
Sergio Serrano, Fred R. Hirsch, F. Solé, Edurne Arriola, Raquel Longarón, Luz Martínez-Avilés, Lara Pijuan, Joan Albanell, Marta Salido, Beatriz Bellosillo, Murry W. Wynes, Ana B. Galván, Israel Cañadas, Ana Rovira, Montserrat Zanui, Alejandro Martinez
Publikováno v:
Journal of Thoracic Oncology. 6:21-27
Introduction: Translocation of the anaplastic lymphoma kinase (ALK) gene is involved in the tumorigenesis of a subset of non-small cell lung carcinomas (NSCLCs) and identifies patients sensitive to ALK inhibitors. ALK copy number changes and amplific
Autor:
David, Benaiges, Montserrat, Zanui, Juan José, Chillaron, Edurne, Arriola, Laia, Garrigos, Juan, Pedro-Botet
Publikováno v:
Investigacion clinica. 53(4)
Metastases in the sellar region are rare and are frequently found incidentally or in necropsies. Only 7% are reported to be symptomatic. Diabetes insipidus, anterior pituitary dysfunction, visual field defects, headache/pain and ophthalmoplegia are t
Publikováno v:
Critical reviews in oncology/hematology. 88(2)
The cornerstone of treatment for early-stage non-small cell lung cancer (NSCLC) has been surgical resection. In the last five years two phase III trials have provided evidence of adjuvant platinum-based chemotherapy for completely resected stage II-I